The complement cascade, a proteolytic network originally characterised for host defence, exerts multifaceted roles within the central nervous system. Under physiological conditions, complement ...

The limited availability of monoclonal antibodies for the treatment of kidney diseases has long been a source of frustration for the nephrology community. However, the emergence of therapies targeting ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket ...